68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Launched by JONSSON COMPREHENSIVE CANCER CENTER · Jun 30, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-FAPi-46 PET/CT scan to help doctors see where sarcoma, a type of cancer, is located in the body and how much of it is present. The scan uses a small amount of a radioactive tracer that can be taken up by cancer cells, making them visible during the imaging process. This technique is designed for patients who have sarcoma that might be new, recurrent, or metastatic (spread to other parts of the body), and it could help doctors better understand the extent of the disease before surgery or a biopsy.

To participate in this trial, you must be at least 18 years old and scheduled for surgery or a biopsy related to suspected sarcoma. You also need to be able to give written consent and stay still during the imaging, which can last up to an hour. However, if you are pregnant, nursing, or recently started new cancer treatments, you may not be eligible for this study. If you join, you can expect to undergo the PET/CT scan, which will help gather important information about your condition and potentially guide your treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are scheduled to undergo surgical excision or biopsy of a suspected sarcoma primary, or a suspected recurrent or metastatic lesion.
• • Patients who are ≥ 18 years old at the time of the radiotracer administration.
• • Patients who can provide written informed consent.
• • Patients who are able to remain still for duration of imaging procedures (up to one hour for each).
• Exclusion Criteria:
• • Patient is pregnant or nursing.
• • Patients with any new cancer therapy between the baseline 18F-FDG PET/CT and the investigational FAPI PET/CT
• • Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high quality data.